Literature DB >> 10724031

The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers.

R Pruchnic1, B Cao, Z Q Peterson, X Xiao, J Li, R J Samulski, M Epperly, J Huard.   

Abstract

Muscle-based gene therapy using adenovirus, retrovirus, and herpes simplex virus has been hindered by viral cytotoxicity, host immune response, and the maturation-dependent viral transduction of muscle fibers. The development of new mutant vectors has greatly reduced the toxicity and the immune rejection problems, but the inability of viral vectors to penetrate and transduce mature myofibers remains an important issue. Research has been focused on the characterization of barriers to viral transduction in mature myofibers to develop strategies to circumvent the maturation-dependent viral transduction of myofibers. Here, we report that adeno-associated virus (AAV) can be used to overcome the maturation-dependent viral transduction of myofibers. We have investigated by which mechanism AAV can penetrate and efficiently transduce mature muscle fibers, and have shown that this viral vector is not blocked by the basal lamina and that AAV transduction of myofibers is independent of myoblast mediation. Although AAV can efficiently transduce mature myofibers, a differential transduction is still observed among the different types of myofibers that correlates with the expression of the heparan sulfate proteoglycan receptors, the muscle maturity, the number of viral particles used, and the time postinjection. The identification of the mechanisms by which AAV transduces mature myofibers will help in the development of strategies to achieve an efficient muscle-based gene therapy for inherited and acquired diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10724031     DOI: 10.1089/10430340050015716

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  18 in total

Review 1.  Adeno-associated virus-mediated gene transfer for hemophilia B.

Authors:  Katherine A High
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.

Authors:  B Wang; J Li; X Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes.

Authors:  Zhijian Wu; Aravind Asokan; Joshua C Grieger; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

4.  Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart.

Authors:  Chunping Qiao; Zhenhua Yuan; Jianbin Li; Ruhang Tang; Juan Li; Xiao Xiao
Journal:  Hum Gene Ther Methods       Date:  2012-02       Impact factor: 2.396

5.  Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy.

Authors:  X Xiao; J Li; Y P Tsao; D Dressman; E P Hoffman; J F Watchko
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation.

Authors:  D Duan; Z Yan; Y Yue; W Ding; J F Engelhardt
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Quantitative 3D tracing of gene-delivery viral vectors in human cells and animal tissues.

Authors:  Ping-Jie Xiao; Chengwen Li; Aaron Neumann; R Jude Samulski
Journal:  Mol Ther       Date:  2011-11-22       Impact factor: 11.454

8.  Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals.

Authors:  A Asokan; J S Johnson; C Li; R J Samulski
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

9.  Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy.

Authors:  Baodong Sun; Sarah P Young; Ping Li; Chunhui Di; Talmage Brown; Maja Z Salva; Songtao Li; Andrew Bird; Zhen Yan; Richard Auten; Stephen D Hauschka; Dwight D Koeberl
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

10.  Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model.

Authors:  Valder R Arruda; Hansell H Stedman; Timothy C Nichols; Mark E Haskins; Matthew Nicholson; Roland W Herzog; Linda B Couto; Katherine A High
Journal:  Blood       Date:  2004-10-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.